Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: T-Therapeutics Series A extension to $91m
Lucid Diligence Brief: T-Therapeutics Series A extension to $91m Professional…
Lucid Diligence Brief: General Proximity and Daiichi Sankyo multi-target induced-proximity oncology deal
Lucid Diligence Brief: General Proximity and Daiichi Sankyo multi-target…
Lucid Diligence Brief: Galecto acquires Damora Therapeutics
Lucid Diligence Brief: Galecto acquires Damora Therapeutics Professional…
Lucid Diligence Brief: Iambic raises $100M+ for AI drug discovery
Lucid Diligence Brief: Iambic raises $100M+ for AI drug discovery Professional…
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding Professional audiences…
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing…
Lucid Diligence Brief: NEOK Bio $75M Series A
Lucid Diligence Brief: NEOK Bio $75M Series A Professional audiences only. Not…
Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027
Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027 Professional…